Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2011
Filing Date: March 13, 2012
Accounting Basis: International Financial Reporting Standards (IFRS)
Outstanding Shares: 5,049,045,171 Ordinary Shares (Par value 25 pence)
GSK is a science-led global healthcare company operating in pharmaceuticals, vaccines, and consumer healthcare. The filing incorporates the "GSK Annual Report 2011" by reference for detailed operational and financial data.
Key Financial Metrics
Note: Specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in the cover sheet text of this Form 20-F. These figures are incorporated by reference from the GSK Annual Report 2011 (pages 136-215 and 232-234).
- Revenue, Profit, and Margins: Refer to "Consolidated income statement" (pages 136-137) and "Five year record" (pages 232-234) in the incorporated Annual Report.
- Cash Flow: Refer to "Consolidated cash flow statement" (page 140) in the incorporated Annual Report.
- Debt and Liquidity: Refer to "Consolidated balance sheet" (page 138) and "Financial position" (pages 61-66) in the incorporated Annual Report.
- Dividends: Dividend information is incorporated by reference from page 242 of the Annual Report.
Material Changes and Significant Events
The filing indicates that significant changes and post-balance sheet events are detailed in "Note 40 - Post balance sheet events" on page 191 of the incorporated Annual Report. The text does not explicitly list specific material changes in the cover sheet.
Guidance, Outlook, and Risks
Outlook and Management Commentary:
- Management commentary, including the Chairman's statement and Chief Executive's review, is incorporated from pages 10-12 of the Annual Report.
- Trend information and financial reviews for 2011 and 2010 are incorporated from pages 51-71 and 222-231.
- R&D investment and pipeline details are incorporated from pages 30-37.
Risks and Contingencies:
- Risk factors are incorporated from pages 72-77 of the Annual Report.
- Legal proceedings are detailed in "Note 44" on pages 208-215.
- Market risk disclosures (treasury policies and financial instruments) are incorporated from pages 65-66 and 192-201.
Investor Verification Checklist
- Financial Performance: Verify specific revenue, operating profit, and net income figures in the "Consolidated income statement" (pages 136-137 of the Annual Report).
- Debt Obligations: Review the "Consolidated balance sheet" (page 138) and "Contractual obligations" (page 63) for total debt levels and maturity profiles.
- Legal Exposure: Examine "Note 44 - Legal proceedings" (pages 208-215) for details on ongoing litigation and potential liabilities.
- Internal Controls: Confirm the effectiveness of internal controls over financial reporting as certified by the CEO and CFO and audited by PricewaterhouseCoopers LLP (Item 15).
- Corporate Governance: Review the comparison of GSK's governance practices against NYSE standards (Item 16.G), noting compliance with the UK Corporate Governance Code.
- ADR Fees: Note that ADR holders may be charged fees up to $0.05 per ADR for issuance or withdrawal, plus other potential expenses (Item 12.D).